Loading...
Loading...
In a report published Friday, Jefferies & Company reiterated its Buy rating on DexCom
DXCM, but lowered its price target from $18.00 to $16.50.
Jefferies noted, “DexCom released final 3Q revenues of $23.1mn after pre-announcing in early October with the G4 Platinum Sensor approval. The final 3Q numbers reflect a handful of one-time charges and adjustments; full year guidance was reiterated. The G4 and the subsequent pump combinations set the table for a good run.”
DexCom closed on Thursday at $13.07.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in